Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
View Patent ↗An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells. As well as the use of the polypeptide in the treatment of a disorder associated with impaired glucose metabolism.
1. An isolated polypeptide consisting of a fragment of unacylated ghrelin as set forth in SEQ ID NO: 1, said fragment being 5-18 amino acids in length and comprising amino acid sequence Glu-His-Gln-Arg-Val as set forth in SEQ ID NO: 8 or an analog thereof and having an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion and/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells; and wherein said polypeptide does not comprise an amino acid sequence consisting of amino acids Gly-Ser-Ser-Phe.
2. The isolated polypeptide of claim 1 , wherein said polypeptide comprises amino acid sequence Glu-His-Gln-Arg-Val-Gln as set forth in SEQ ID NO: 7 or an analog thereof.
3. The isolated polypeptide of claim 1 , wherein said polypeptide comprises amino acid sequence Ser-Pro-Glu-His-Gln-Arg-Val-Gln as set forth in SEQ ID NO: 6 or an analog thereof.
4. The isolated polypeptide of claim 1 , wherein said polypeptide comprises amino acid sequence Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser as set forth in SEQ ID NO: 9 or an analog thereof.
5. The isolated polypeptide of claim 4 consisting of any consecutive 5 amino acid residues of the amino acid sequence Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser as set forth in SEQ ID NO: 9.
6. The isolated polypeptide of claim 1 , wherein said polypeptide consists of an amino acid sequence selected from the group consisting of Glu-His-Gln-Arg-Val as set forth in SEQ ID NO: 8, Glu-His-Gln-Arg-Val-Gln as set forth in SEQ ID: NO 7, Ser-Pro-Glu-His-Gln-Arg-Val-Gln as set forth in SEQ ID NO: 6, Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser as set forth in SEQ ID NO: 9.
7. The isolated polypeptide of claim 1 , wherein said polypeptide consists of a fragment having 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 amino acids.
8. A method for treating a disorder associated with increased blood glucose levels in a patient comprising administering to the patient a therapeutically effective amount of the polypeptide of claim 1 .
9. The method of claim 8 , wherein the disorder is diabetes.
10. The method of claim 9 , wherein the diabetes is type 1 diabetes.
11. The method of claim 9 , wherein the diabetes is type 2 diabetes.
12. The method of claim 8 , wherein the disorder is a medical condition associated with insulin deficiencies.
13. The method of claim 8 , wherein the disorder is a medical condition associated with dyslipidemia.
14. The method of claim 8 , wherein the disorder is a medical condition associated with obesity.
15. The method of claim 8 , wherein the disorder is a medical condition related to metabolic syndrome.
16. The method of claim 8 , wherein the treatment is through enhancement of proliferation or of survival of the pancreatic β-cells.
17. The method of claim 8 , wherein the polypeptide is administered through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal delivery and inhalation.
18. The method of claim 8 , wherein the polypeptide is administered in a dose varying from about 0.01 μg/kg to about 10 mg/kg.
19. A method of treating insulin resistance in a patient comprising administering to the patient a therapeutically effective amount of the polypeptide of claim 1 .
20. The method of claim 19 , wherein said polypeptide comprises amino acid sequence Ser-Pro-Glu-His-Gln-Arg-Val-Gln as set forth in SEQ ID NO: 6 or an analog thereof.
21. The isolated polypeptide of claim 1 , for treating a disorder associated with increased blood glucose metabolism in a patient.
22. The isolated polypeptide of claim 21 , wherein the disorder is type II diabetes.
23. The isolated polypeptide of claim 21 , wherein the disorder is obesity.
24. A pharmaceutical composition for treating a disorder associated with increased blood glucose levels comprising a therapeutically effective amount of the isolated polypeptide of claim 1 .
25. The isolated polypeptide of claim 1 wherein the polypeptide is cyclized.
26. The isolated polypeptide of claims 1 wherein the polypeptide is linked to a linker moiety.
27. An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28.
28. An isolated polypeptide consisting of an amino acid sequence as set forth in SEQ ID NO: 6 and wherein the polypeptide is cyclized.